EGFR and non-small cell lung carcinoma: In this study, we assessed the effect of AI eligibility in patients with an EGFR‐mutant NSCLC who had been treated with EGFR‐TKI monotherapy and evaluated the impact of AI eligibility for different EGFR mutation subtypes.